Clinical Trial Update: A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of emicizumab in people with Hemophilia A without FVIII inhibitors completed; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Emicizumab (emicizumab)
• Hemlibra (emicizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor | Phase 3 | Status: COMPLETED | Results posted: 2022-12-15